We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Armata Pharmaceuticals, Inc. (ARMP - Free Report) shares ended the last trading session 103.2% higher at $7.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.8% gain over the past four weeks.
The massive stock price surge was observed after the company reported positive mid-stage results for its investigational bacteriophage therapy, AP-SA02, targeting Staphylococcus aureus bacteremia (SAB). The late-breaking data, presented at IDWeek 2025, demonstrated significantly higher cure rates and zero relapse among patients treated with AP-SA02 in combination with standard antibiotic therapy, compared to placebo. The treatment also showed a favorable safety profile with no serious drug-related adverse events. Importantly, the study marked the first randomized clinical study to confirm the efficacy of intravenous phage therapy for S. aureus infections, highlighting its potential as a novel approach against antibiotic-resistant bacteria. The findings reinforce Armata’s plan to advance AP-SA02 into a pivotal phase III study in 2026, pending alignment with the FDA, fueling investor optimism over the company’s leadership in next-generation antibacterial therapeutics.
This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -180%. Revenues are expected to be $1.38 million, down 53.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Armata Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARMP going forward to see if this recent jump can turn into more strength down the road.
Armata Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, NeoGenomics (NEO - Free Report) , closed the last trading session 0.9% lower at $10.34. Over the past month, NEO has returned 28.3%.
NeoGenomics' consensus EPS estimate for the upcoming report has changed +5.7% over the past month to $0.02. Compared to the company's year-ago EPS, this represents a change of -60%. NeoGenomics currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains?
Armata Pharmaceuticals, Inc. (ARMP - Free Report) shares ended the last trading session 103.2% higher at $7.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.8% gain over the past four weeks.
The massive stock price surge was observed after the company reported positive mid-stage results for its investigational bacteriophage therapy, AP-SA02, targeting Staphylococcus aureus bacteremia (SAB). The late-breaking data, presented at IDWeek 2025, demonstrated significantly higher cure rates and zero relapse among patients treated with AP-SA02 in combination with standard antibiotic therapy, compared to placebo. The treatment also showed a favorable safety profile with no serious drug-related adverse events. Importantly, the study marked the first randomized clinical study to confirm the efficacy of intravenous phage therapy for S. aureus infections, highlighting its potential as a novel approach against antibiotic-resistant bacteria. The findings reinforce Armata’s plan to advance AP-SA02 into a pivotal phase III study in 2026, pending alignment with the FDA, fueling investor optimism over the company’s leadership in next-generation antibacterial therapeutics.
This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -180%. Revenues are expected to be $1.38 million, down 53.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Armata Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARMP going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Armata Pharmaceuticals belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, NeoGenomics (NEO - Free Report) , closed the last trading session 0.9% lower at $10.34. Over the past month, NEO has returned 28.3%.
NeoGenomics' consensus EPS estimate for the upcoming report has changed +5.7% over the past month to $0.02. Compared to the company's year-ago EPS, this represents a change of -60%. NeoGenomics currently boasts a Zacks Rank of #3 (Hold).